ATOSSA THERAPEUTICS, INC.
ATOSNext catalyst
(Z)-endoxifen
Breast Neoplasms
Get an email about ATOS's next catalysts
Track ATOSSA THERAPEUTICS (ATOS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
ATOS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.86 | FQ end Sep/2026 | Call: tbd
(Z)-endoxifen Phase 2 Est. Readout (EVANGELINE)
Primary completion for (Z)-endoxifen trial (NCT05607004) in Breast Neoplasms
SourceMarket Overview
Stock performance and key metrics
(Z)-endoxifen
Breast Neoplasms
Topical endoxifen
Mammographic Breast Density
Z-Endoxifen
Breast Density
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
(Z)-endoxifen | Phase 2 | Breast Neoplasms | - | - |
Topical endoxifen | Phase 2 | Mammographic Breast Density | - | - |
Z-Endoxifen | Phase 2 | Breast Density | - | - |
Breast Density
1 drug in this indication
Breast Neoplasms
1 drug in this indication
Mammographic Breast Density
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in ATOSSA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in ATOSSA THERAPEUTICS, INC.'s (ATOS) pipeline across Phase 2. Its lead program is (Z)-endoxifen (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ATOSSA THERAPEUTICS, INC.'s next FDA catalyst?→
ATOSSA THERAPEUTICS, INC.'s (ATOS) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ATOS biotech catalysts?→
Add ATOS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ATOSSA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.